Guardian Pharmacy Services, Inc. (GRDN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Guardian Pharmacy Services, Inc. is a leading pharmacy services provider for long-term health care facilities (LTCFs), with a strategic focus on assisted living facilities (ALFs) and behavioral health facilities (BHFs). As of June 30, 2026, the company operated 61 pharmacies serving approximately 210,000 residents across 8,400 LTCFs in 39 states.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) | YoY Change |
|---|---|---|
| Revenues | $688,363 | +2.2% |
| Net Income (GAAP) | $35,665 | +97.0% |
| Net Income Attributable to Guardian | $35,167 | +90.3% |
| Diluted EPS | $0.55 | +89.7% |
| Adjusted EBITDA | $59,416 | +22.8% |
| Operating Cash Flow | $36,087 | -3.7% |
| Cash and Equivalents | $89,807 | +379.9% (vs. Dec 31, 2025) |
| Debt Outstanding | $0 | N/A |
Note: Gross margin improved to 22.7% (from 19.7% in prior year) primarily due to Inflation Reduction Act (IRA) impacts on drug costs.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2.2% year-over-year. However, organic revenue decreased by $17.2 million due to IRA-mandated price reductions. This was offset by $31.9 million in revenue from acquisitions completed in 2025.
- Profitability Surge: Net income nearly doubled, driven significantly by a one-time $8.5 million legal settlement related to a payor-reimbursement matter recorded in "Other expense (income), net."
- Cost Structure: Cost of goods sold (COGS) decreased 1.7% year-over-year, with organic COGS down $35.2 million due to IRA price reductions. SG&A expenses increased 10.4% due to higher employee headcount from organic growth and acquisitions.
- Capital Structure: In March 2026, the company completed a follow-on offering where proceeds were used to repurchase and retire Class A shares issued upon the conversion of Class B stock, resulting in no net change to total Class A shares outstanding.
Guidance, Outlook, and Risks
- IRA Impact: Management expects IRA-related price reductions to continue impacting year-over-year comparability for the remainder of 2026, specifically affecting revenue and COGS.
- Growth Strategy: The company continues to pursue growth through a combination of organic expansion (increasing residents served) and acquisitions of institutional pharmacies.
- Liquidity: The company holds $89.8 million in cash and has a $40 million revolving credit facility (extendable to $80 million) with no current borrowings. Management believes resources are sufficient for the next 12 months.
- Risks: Key risks include the ongoing impact of drug pricing reforms, competition in the LTCF market, reliance on relationships with payors and LTCF operators, and potential supply chain disruptions.
Investor Verification Checklist
- Settlement Sustainability: Verify the non-recurring nature of the $8.5 million legal settlement and its impact on GAAP net income vs. Adjusted EBITDA.
- IRA Pricing Pressure: Assess the long-term impact of Inflation Reduction Act price caps on gross margins and organic revenue growth.
- Acquisition Integration: Review the performance of 2025 acquisitions to ensure they are delivering expected synergies and offsetting organic revenue declines.
- Share Count Dynamics: Confirm the status of Class B to Class A conversions and any future dilution from the 2024 Equity and Incentive Compensation Plan.
- Working Capital Trends: Monitor accounts receivable and payable trends, as timing differences related to the IRA impacted operating cash flow in the current period.